HK1177461A1 - -氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用 - Google Patents
-氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用Info
- Publication number
- HK1177461A1 HK1177461A1 HK13104640.1A HK13104640A HK1177461A1 HK 1177461 A1 HK1177461 A1 HK 1177461A1 HK 13104640 A HK13104640 A HK 13104640A HK 1177461 A1 HK1177461 A1 HK 1177461A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyridylmethoxy
- enamide
- methylpyrrolidin
- quinolyl
- prop
- Prior art date
Links
- SADXACCFNXBCFY-IYNHSRRRSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\[C@@H]3N(CCC3)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 SADXACCFNXBCFY-IYNHSRRRSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100623598A CN102675287A (zh) | 2011-03-11 | 2011-03-11 | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 |
| PCT/CN2012/071015 WO2012122865A2 (zh) | 2011-03-11 | 2012-02-10 | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1177461A1 true HK1177461A1 (zh) | 2013-08-23 |
Family
ID=46807903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13104640.1A HK1177461A1 (zh) | 2011-03-11 | 2013-04-17 | -氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130338190A1 (zh) |
| EP (1) | EP2684877B1 (zh) |
| JP (1) | JP6192544B2 (zh) |
| KR (1) | KR101871889B1 (zh) |
| CN (2) | CN102675287A (zh) |
| ES (1) | ES2605564T3 (zh) |
| HK (1) | HK1177461A1 (zh) |
| PL (1) | PL2684877T3 (zh) |
| PT (1) | PT2684877T (zh) |
| RU (1) | RU2583056C2 (zh) |
| TW (1) | TWI530288B (zh) |
| WO (1) | WO2012122865A2 (zh) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103539783A (zh) * | 2012-07-12 | 2014-01-29 | 江苏恒瑞医药股份有限公司 | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 |
| EP3378478B1 (en) * | 2016-01-27 | 2022-05-11 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising quinoline derivative or salt thereof |
| CN107405345A (zh) | 2016-01-27 | 2017-11-28 | 江苏恒瑞医药股份有限公司 | 一种含有喹啉衍生物或其盐的药物组合物的制备方法 |
| CN112426424A (zh) * | 2016-01-28 | 2021-03-02 | 江苏恒瑞医药股份有限公司 | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 |
| CA3021471A1 (en) | 2016-04-28 | 2017-11-02 | Guaili Wu | Method for preparing tyrosine kinase inhibitor and derivative thereof |
| CN107638424B (zh) * | 2016-07-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗癌症的药物中的用途 |
| TW201827050A (zh) * | 2017-01-22 | 2018-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｅｇｆｒ／ｈｅｒ２抑制劑聯合嘧啶類抗代謝藥物的用途 |
| KR20200072491A (ko) | 2017-10-18 | 2020-06-22 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 티로신 키나제 억제제 및 이의 중간체의 제조 방법 |
| KR20200078561A (ko) | 2017-10-24 | 2020-07-01 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 퀴놀린 유도체를 함유하는 약학 조성물 |
| JP2021503506A (ja) * | 2017-11-20 | 2021-02-12 | テリジーン リミテッドＴｅｌｉｇｅｎｅ Ｌｔｄ． | （ｅ）−ｎ−（３−シアノ−７−エトキシ−４−（（４−フェノキシフェニル）アミノ）キノリン−６−イル）−４−（ジメチルアミノ）ブタ−２−エンアミドのマレイン酸塩及びその結晶形態 |
| US10857146B2 (en) | 2018-08-21 | 2020-12-08 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor |
| CN110960529A (zh) * | 2018-09-30 | 2020-04-07 | 江苏恒瑞医药股份有限公司 | 一种降低了毒性杂质含量的酪氨酸激酶抑制剂的原料药 |
| MX2021004600A (es) * | 2018-10-22 | 2021-06-15 | Jiangsu Hengrui Medicine Co | Forma cristalina del inhibidor de maleato de tirosina quinasa y metodo de preparacion para el mismo. |
| CN111821304A (zh) * | 2019-04-16 | 2020-10-27 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途 |
| TW202115027A (zh) * | 2019-08-30 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 低雜質含量的酪胺酸激酶抑制劑 |
| CN112279838B (zh) * | 2020-10-29 | 2021-07-13 | 苏州富士莱医药股份有限公司 | 一种吡咯替尼的制备方法 |
| CN114409584A (zh) * | 2022-03-08 | 2022-04-29 | 重庆医药高等专科学校 | 一种1-甲基吡咯烷-2-甲醛的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| KR100486394B1 (ko) * | 1999-11-16 | 2005-04-29 | 쉬바르츠파르마에이지 | 3,3-디페닐-프로필아민의 신규한 유도체의 안정한 염 |
| KR20050044599A (ko) * | 2001-11-27 | 2005-05-12 | 와이어쓰 홀딩스 코포레이션 | Ｅｇｆ-ｒ 및 ｈｅｒ2 키나아제의 억제제로서의3-시아노퀴놀린 |
| DE10307165A1 (de) * | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| CN100540552C (zh) | 2007-02-01 | 2009-09-16 | 中国药科大学 | 3-氰基喹啉衍生物、其制备方法及其医药用途 |
| US8022216B2 (en) * | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN101824029A (zh) * | 2009-03-05 | 2010-09-08 | 厦门艾德生物医药科技有限公司 | 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途 |
| CN102020639A (zh) * | 2009-09-14 | 2011-04-20 | 上海恒瑞医药有限公司 | 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用 |
| CN107441058A (zh) * | 2009-11-09 | 2017-12-08 | 惠氏有限责任公司 | 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途 |
-
2011
- 2011-03-11 CN CN2011100623598A patent/CN102675287A/zh active Pending
-
2012
- 2012-02-10 PL PL12757831T patent/PL2684877T3/pl unknown
- 2012-02-10 WO PCT/CN2012/071015 patent/WO2012122865A2/zh active Application Filing
- 2012-02-10 EP EP12757831.8A patent/EP2684877B1/en active Active
- 2012-02-10 RU RU2013143381/04A patent/RU2583056C2/ru active
- 2012-02-10 ES ES12757831.8T patent/ES2605564T3/es active Active
- 2012-02-10 JP JP2013556950A patent/JP6192544B2/ja not_active Expired - Fee Related
- 2012-02-10 PT PT127578318T patent/PT2684877T/pt unknown
- 2012-02-10 CN CN201280001564.6A patent/CN102933574B/zh active Active
- 2012-02-10 KR KR1020137025507A patent/KR101871889B1/ko active IP Right Grant
- 2012-02-10 US US14/001,778 patent/US20130338190A1/en not_active Abandoned
- 2012-02-24 TW TW101106172A patent/TWI530288B/zh active
-
2013
- 2013-04-17 HK HK13104640.1A patent/HK1177461A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP6192544B2 (ja) | 2017-09-06 |
| JP2014507448A (ja) | 2014-03-27 |
| ES2605564T3 (es) | 2017-03-15 |
| TWI530288B (zh) | 2016-04-21 |
| EP2684877A4 (en) | 2014-08-06 |
| RU2583056C2 (ru) | 2016-05-10 |
| TW201236684A (en) | 2012-09-16 |
| PL2684877T3 (pl) | 2017-05-31 |
| CN102675287A (zh) | 2012-09-19 |
| WO2012122865A3 (zh) | 2012-11-08 |
| KR101871889B1 (ko) | 2018-06-27 |
| EP2684877A2 (en) | 2014-01-15 |
| EP2684877B1 (en) | 2016-10-19 |
| PT2684877T (pt) | 2017-01-18 |
| WO2012122865A2 (zh) | 2012-09-20 |
| RU2013143381A (ru) | 2015-04-20 |
| CN102933574B (zh) | 2014-10-01 |
| US20130338190A1 (en) | 2013-12-19 |
| KR20140009418A (ko) | 2014-01-22 |
| CN102933574A (zh) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1177461A1 (zh) | -氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用 | |
| IL229199A (en) | N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs | |
| EP2769976B8 (en) | Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof | |
| CY1118839T1 (el) | Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη | |
| BR112014003802A2 (pt) | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| CY1121421T1 (el) | Φαρμακοτεχνικες μορφες | |
| BR112014008126A2 (pt) | composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção | |
| CL2013001381A1 (es) | Compuestos derivados de hidroxi-amida pirimidina, inhibidores de la proteina deacetilasa hdac6; composicion farmaceutica; combinación farmaceutica; metodos de uso para el tratamiento de una enfermedad proliferativa o cancer; un kit | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| IL231495B (en) | N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compounds or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of osteoporosis | |
| BR112013009970A2 (pt) | método para determinar uma característica do ritmo circadiano de um paciente. | |
| GB2505860B (en) | Aripiprazole medicament formulation and preparation method therefor | |
| ZA201307688B (en) | Pharmaceutically acceptable cocrystals of n-[2-(7-methoxy-1-naphtyl)ethyl] acetamide and methods of their preparation | |
| IL230487B (en) | 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them | |
| CY1123700T1 (el) | Παιδιατρικη φαρμακοτεχνικη μορφη | |
| IL230484A (en) | "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation | |
| EP2781512A4 (en) | OXADIAZOLE COMPOUND AND PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| ZA201303695B (en) | Pharmaceutical composition comprising citrate and bicarbonate salts,and use thereof for treating cystinuria | |
| BR112012033121A2 (pt) | métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório. | |
| BR112013019775A2 (pt) | composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente | |
| BR112013017184A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças | |
| MX2013006031A (es) | Formulacion liposomal de dalcetrapib. | |
| HUP1100351A2 (en) | Process for the preparation of (5alpha,17beta)-n-[2,5-bis-(trifluoromethyl)-phenyl]-3-oxo-4-aza-5-androst-1-en-17-carboxylic amide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20240212 |